Erschienen in:
11.07.2019 | Current Controversies (P Kleinplatz and C Moser, Section Editors)
Update on Sexual Dysfunction Associated with Psychotropic Medications and Its Treatment
verfasst von:
Richard Balon
Erschienen in:
Current Sexual Health Reports
|
Ausgabe 3/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
The goal of this review was to evaluate recent developments in sexual dysfunction associated with psychotropic medications and its management.
Recent Findings
Sexual dysfunction associated with psychotropic medications is a serious clinical problem which occurs mostly with antidepressants, especially serotonergic ones, and antipsychotics, especially those causing hyperprolactinemia. Sexual dysfunction(s) seems to be associated to a significantly lesser degree with some newer psychotropic medications, e.g., vilazodone, vortioxetine, and agomelatine among antidepressants, and aripiprazole and lurasidone among antipsychotics. There have been no significant new developments in management of sexual dysfunction(s) associated with psychotropic medications with the exception of using newer medications or switching to them. A new clinical phenomenon—post serotonin reuptake inhibitors sexual dysfunction—has emerged as a difficult management issue.
Summary
Sexual dysfunction associated with psychotropic medications continues to be an important issue requiring further research to provide solid evidence for regulatory agencies and for clinicians.